Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get Nature's Evidence-Based Pharmacy

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Download Now

500+ pages of Natural Medicine Alternatives and Information.

n/a
Article Publish Status: FREE
Abstract Title:

Do Gadolinium-Based Contrast Agents AffectF-FDG PET/CT Uptake in the Dentate Nucleus and the Globus Pallidus? A Pilot Study.

Abstract Source:

J Nucl Med Technol. 2017 03 ;45(1):30-33. Epub 2016 Nov 10. PMID: 27834725

Abstract Author(s):

Kyle Bauer, Alaina Lathrum, Osama Raslan, Patrick V Kelly, Yihua Zhou, Debra Hewing, Crystal Botkin, James A Turner, Medhat Osman

Article Affiliation:

Kyle Bauer

Abstract:

Gadolinium is toxic and to avoid its deposition in tissues, it must be chemically bonded with nonmetal ions to facilitate its excretion by the kidneys. High signal intensity in the dentate nucleus (DN) and globus pallidus (GP) on unenhanced T1-weighted MR images has been both morphologically and pathologically linked to gadolinium-based contrast agent (GBCA) retention in the brain. The purpose of this study was to determine whether repeated administrations of GBCA would affect the uptake ofF-FDG in the DN and GP on PET/CT.Three hundred seventy-six patients who underwent both contrast-enhanced MR (CE MR) of the brain and PET/CT from January 2004 to October 2015 were identified. Patients with a history of brain irradiation or hepatic or renal disease were excluded. The SUVwas measured in the DN and GP on the PET/CT scan in patients who had 3-6 successive CE MR brain studies. The SUVof the corresponding areas in the control group of patients who had not undergone previous CE MR and who had a normal, unenhanced MR finding of the brain was also measured. A Wilcoxon 2-sample test was used for statistical analysis.Fifteen of 376 (4%) patients (mean age± SD, 54 ± 18 y; 10 men and 5 women) were included in the subject group, and 15 patients (mean age ± SD, 36 ± 9 y; 11 men and 4 women) were included in the control group. The median DN SUVwas significantly lower in the subject group than in the control group (5.4 vs. 6.4, respectively;= 0.021). Similarly, the median GP SUVwas significantly lower in the subject group than in the control group (8.8 vs. 12.1, respectively;= 0.003).The median SUVin the DN and GP was 16% and 27% lower, respectively, in patients who received GBCAs than in those who had not received GBCAs, possibly related to gadolinium deposition in these areas.

Study Type : Human Study
Additional Links
Problem Substances : Gadolinium : CK(1) : AC(1)
Adverse Pharmacological Actions : Neurotoxic : CK(1458) : AC(323)

Print Options


Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get Nature's Evidence-Based Pharmacy

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Download Now

500+ pages of Natural Medicine Alternatives and Information.

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2019 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.